Novo Nordisk has announced a partnership with BE&K Building Group to manage the construction of a new multi-product facility in Clayton, North Carolina. This significant development will expand Novo Nordisk’s existing operations in the area. The project entails the construction
Novo Nordisk has announced plans to invest $4.1 billion to build a second fill and finish manufacturing facility in Clayton, North Carolina. This expansion aims to increase production capacity for current and future injectable treatments for obesity and other serious
What happened? Catalent, involved in producing Novo Nordisk’s top-selling GLP-1 obesity drug Wegovy, has over 50 sites globally. The acquisition follows Catalent’s strategic review due to declining revenue and issues at major manufacturing sites. The purchase price of $63.5 per
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
